Tesamorelin

Product Overview

Tesamorelin is a synthetic version of GHRH that stimulates the pituitary gland to produce and release HGH naturally. Unlike direct HGH injections that can shut down the body's own hormone production, tesamorelin keeps the natural regulatory system intact. Its effects are regulated by somatostatin negative feedback, making overdose difficult and preserving natural GH pulse patterns. It also stimulates hGH gene transcription, maintaining the growth hormone neuroendocrine axis.

Mechanism of Action

Tesamorelin binds to GHRH receptors on pituitary somatotroph cells, triggering natural pulsatile HGH release. The resulting HGH elevation boosts IGF-1 levels, which together increase fat metabolism (particularly visceral fat), support muscle maintenance, and promote tissue repair. Somatostatin feedback prevents overstimulation.

Key Benefits

Visceral Fat Reduction — Specifically targets visceral abdominal fat, the most metabolically dangerous fat type. Originally FDA-approved for HIV-associated lipodystrophy.

Metabolic Enhancement — Boosts muscle mass and revs metabolism. Improves blood sugar utilization and reduces triglycerides for better overall metabolic health.

Cognitive Function — 20 weeks of GHRH supplementation increases GABA function, supporting mental capacity, memory, mood, and reduced cognitive disorders.

Skin & Anti-Aging — HGH influences collagen and elastin gene expression, keeping skin plump and youthful. Protects cells against damage and death.

Nerve Health — GHRH secretagogues may aid nerve regeneration, offering safer alternatives for peripheral neuropathy treatment.

References

1. Stanley TL, et al. Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin. *Clin Infect Dis.* 2012;54(11):1642–1651.
2. Adrian S, et al. Tesamorelin decreases muscle fat and increases muscle area in adults with HIV. *J Frailty Aging.* 2019;8(3):154–159.
3. Wang L, et al. Therapeutic peptides: current applications and future directions. *Signal Transduct Target Ther.* 2022;7(1):1–27.